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Abstract
Methadone is increasingly prescribed for chronic pain, yet the associated mortality appears to be
rising disproportionately relative to other opioid analgesics. We review the available evidence on
methadone-associated mortality, and explore potential pharmacokinetic and pharmacodynamic
explanations for its greater apparent lethality. While methadone shares properties of central
nervous system and respiratory depression with other opioids, methadone is unique as a potent
blocker of the delayed rectifier potassium ion channel (IKr). This results in QT-prolongation
and torsade de pointes (TdP) in susceptible individuals. In some individuals with low serum
protein binding of methadone, the extent of blockade is roughly comparable to that of sotalol,
a potent QT-prolonging drug. Predicting an individual’s propensity for methadone-induced
TdP is difficult at present given the inherent limitations of the QT interval as a risk-stratifier
combined with the multifactorial nature of the arrhythmia. Consensus recommendations have
recently been published to mitigate the risk of TdP until further studies better define the
arrhythmia risk factors for methadone. Studies are needed to provide insights into the clinical
covariates most likely to result in methadone-associated arrhythmia and to assess the feasibil-
ity of current risk mitigation strategies. (Cardiol J 2009; 16, 3: 210–217)
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Introduction
Chronic pain is one of the most common clini-
cal problems encountered in modern medicine [1].
When pain is acute, the causes are typically appa-
rent and the treatment is simple and straightfor-
ward. But when pain becomes entrenched, the pain
signals can ‘hijack’ the nervous system for weeks,
months or even years, approaching permanence for
certain patients. Various treatments are often at-
tempted prior to referral to a chronic pain practitio-
ner. Therapies attempted may include medication,
acupuncture, local electrical stimulation, brain sti-
mulation, psychotherapy, relaxation, biofeedback,
behavior modification and various other comple-
mentary and alternative therapies. As the cycle of
The greatest evil is physical pain
[St Augustine, Soliloquies I, 21]
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pain continues, the neurologic pathways become
more reinforced and threaten a patient’s chance of
returning to his or her pain-free baseline. Over the
last ten years, physicians have increasingly reco-
gnized the need for opioid-based regimens to com-
bat severe chronic pain [2], yet this has inadverten-
tly led to both increased use and mortality attribu-
ted to prescribed opioids.
The use of methadone for chronic pain
Methadone use for the treatment of chronic
pain has increased dramatically since 1997 [3]
across the United States, in part due to its low cost,
long half-life and added effectiveness in modulating
pain. Chronic opioid use results in both tolerance
to its anti-nociceptive effects as well as heightened
sensitivity to pain. These undesirable effects are
multifactorial, involving downregulation and desen-
sitization of opiate receptors, an effect that appears
dependent on the stimulation of the glutaminergic
NMDA receptor [4]. Not only is methadone a m-opia-
te receptor agonist (ten times more potent than
morphine), it is also an NMDA receptor antagonist,
and appears significantly less prone to induction of
post-opioid hyperalgesia [5]. Methadone appears
therefore to be particularly well-suited to treating
chronic pain that has a neuropathic component [6].
Common side effects of methadone are typical for
opioids and include constipation, dizziness, drowsi-
ness, itching, nausea, urine retention, and vomiting.
Yet with methadone there appears to be less consti-
pation and a reduced level of tolerance to its analge-
sic effects compared with other opioids [7]. Signs of
overdose include shallow breathing, extreme fatigue,
dizziness, somnolence, and mental confusion [8].
Methadone and opioid-related mortality
Methadone and opioid associated mortality ra-
tes are increasing across the United States. In 2005,
drug poisoning surpassed hand guns as a cause of
death. While total poisonings increased by 66% from
1997 to 2005, methadone-related deaths increased
by 468% [9]. In West Virginia, opioids were invo-
lved in 93% of all unintentional fatal poisonings in
2006, and methadone was found in 40% of cases,
despite being significantly less frequently prescri-
bed [10]. Approximately 250,000 patients receive
methadone through opioid dependency programs
[11] and > 700,000 for chronic pain [12]. In Utah,
prescriptions for methadone rose by 727% from
1997 to 2004, yet non-suicide methadone related
deaths rose by 1770% in same period [13]. While
approximately ten times the number of prescrip-
tions are written for hydrocodone and oxycodone
compared to methadone, and ten times as many
Americans report abusing these agents compared
to methadone, the total number of deaths in 2005
was only 12% higher for these compounds than
methadone [9]. In 2002, less than 6% of the total
morphine equivalents prescribed in the US were
attributed to methadone [14], but 24% of the opio-
id-related deaths involved methadone.
During a four year prospective study evaluating
patients who had sudden cardiac death in and
around Portland, Oregon, it was shown that 72 of
178 sudden deaths had methadone in their blood.
Of those with methadone in the therapeutic range,
77% had no cardiac abnormalities found at autopsy,
and only one had an additional opioid (oxycodone).
Their conclusion was, given the significantly lower
prevalence of structural heart disease in the me-
thadone group, that even at therapeutic levels, me-
thadone was a likely cause of sudden death [15].
These data suggest strongly that methadone is
significantly more toxic than other opioids, but does
not definitively suggest that the nature of its toxicity
is cardiac in origin.
Pharmacokinetic properties
Methadone has unusual pharmacokinetic pro-
perties that contribute to unintentional toxicity.
Methadone’s elimination half-life (8–130 h) is longer
than its duration of analgesic action (4–8 h) [8, 16].
This discrepancy can require up to four times daily
dosing for chronic pain and can result in significant
systemic accumulation of the drug. Methadone is
metabolized by hepatic cytochromes CYP3A4 and
CYP2D6, and many common medications (e.g.
ciprofloxacin, fluconazole, fluoxetine) can inhibit its
metabolism, causing elevated serum levels and
unanticipated side effects [17]. Approximately
90% of the drug remains protein-bound but a six fold
variance between subjects has been described [18].
In-vitro cardiac repolarization properties
Unlike other available opioids, methadone is
a particularly potent blocker of the IKr channel, and
10 mM of methadone will cause a 50% reduction in
the current. Of currently used opioids, only metha-
done’s clinical serum levels (Cmax) are close to the
IC50 for the human Ether-à-go-go Related Gene
(hERG) potassium channel current (IhERG) [19].
Interestingly, methadone and the potent IKr bloc-
ker terfenadine are molecularly similar in that they
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contain a bi-phenyl structure (Fig. 1), while mor-
phine does not.
Mechanism of torsade de pointes
A QTc greater than 500 ms is thought to indi-
cate a threshold of increased danger for torsade de
pointes (TdP). In the long-QT syndrome registry,
those with a QTc > 500 ms had a four fold greater
risk of sudden death compared to a QTc of 450 ms.
The QTc is the rate corrected QT interval calcula-
ted by QT/÷RR. In the sotalol package insert, a QTc
between 500 and 525 ms was associated with a 3.4%
incidence of TdP (Table 1) [20]. The Antzelevich
laboratory has provided a powerful paradigm for un-
derstanding the mechanism by which QTc interval
prolongation promotes the induction of reentrant
tachyarrhythmias in the absence of structural heart
disease. Their elegant work has demonstrated in-
trinsic heterogeneity of repolarization across the
layers of the ventricle such that the cells of the
middle (‘M’) layer have the longest action poten-
tials while the epicardium has the shortest. The
morphology of the T wave is determined by this
difference between the repolarization of the M and
epicardial layers of the heart. This heterogeneous
electrophysiology of the myocardial layers results
in transmural dispersion of repolarization (TDR)
which can promote the induction of reentry [21].
There are two components of the delayed rectifier
potassium current, the IKr (rapid) and IKs (slow).
These play a dominant role in the repolarization of
the action potential and are important determinants
of its duration [22]. Due to the presence of decre-
ased repolarizing IKs current and increased depo-
larizing late INa and sodium-calcium exchange
currents in M cells, the midmyocardial layer is
particularly susceptible to drugs that block IKr,
resulting in a greater delay of repolarization com-
pared to the epicardial layer and increased TDR. If
TDR is large enough and a premature depolariza-
tion occurs, the midmyocardial layer may still be
refractory to depolarization and thus block the
impulse, causing it to travel in parallel fashion until
excitable tissue is found [23]. Once found, a re-en-
trant circuit is established causing a rotor-like pat-
tern of depolarization which processes through the
ventricle, giving the characteristic polymorphic
pattern of TdP on the surface electrocardiogram
(ECG). Drugs which block IKr but also reduce
inward currents, such as ranolazine, verapamil, and
Figure 1. Comparison of the chemical structure of methadone with LAAM and terfenadine, two other known potent
blockers of the hERG-related channel, IKr. Note that they share a bi-phenyl ring structure, while morphine, a weak
hERG blocker does not.
Table 1. Relationship between QTc and torsade
de pointes (TdP) with d-Sotalol [20].
On-therapy Incidence Change Incidence
QTc of TdP baseine of TdP
[ms]
< 500 1.3% < 65 1.6%
(1787) (1516)
500–525 3.4% 65–80 3.2%
(236) (158)
525–550 5.6% 80–100 4.1%
(125) (146)
> 550 10.8% 100–130 5.2%
(157) (115)
Number of > 130 7.1%
patients assessed (99)
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amiodarone, may increase the QTc interval but do
not increase TDR. This provides a possible expla-
nation for the paucity of reports associating these
drugs with TdP. It is not known whether methado-
ne increases TDR; early reports attribute calcium
channel blocking actions to methadone, which mi-
ght counterbalance the drug’s effect on IKr [24, 25].
Clearly the mechanism by which drug-induced
QTc prolongation leads to TdP is complex and
multifactorial. Typically it requires the presence of
a hERG blocking drug and some other undesirable
co-factor. The most powerful predisposing co-fac-
tor is the presence of an unsuspected hERG muta-
tion (0.1–1% of population), the gene that encodes
formation of the IKr channel on cardiomyocites.
This mutation may result in a dysfunctional protein
increasing the sensitivity of the channel to blockade
by drugs. A pre-existing QTc > 450 ms has been
associated with a significantly increased risk
of sudden cardiac death as well as an increased risk
of TdP. In a meta-analysis of 1288 patients who re-
ceived the QTc interval–prolonging drug sotalol, an
increased pretreatment QTc interval was the stron-
gest predictor of arrhythmia (mean QTc interval of
455 ms in those experiencing TdP vs. 428 ms),
which occurred in 2% of the overall cohort [26].
A study of the antiarrhythmic drug dofetilide found
a doubled risk of sudden death if the pretreatment
QTc interval exceeded the upper quartile value of
479 ms, highlighting the importance of pretreat-
ment ECG screening for identifying susceptible
patients [27]. Other risk factors for TdP include
hypokalemia, hypomagnesemia, female gender,
inhibition of drug metabolism, cardiac ischemia,
congestive heart failure, bradycardia, liver disease
(e.g. cirrhosis), and anorexia nervosa [25, 28, 29].
Methadone’s association
with QTc prolongation
In assessing the in vivo evidence for QTc pro-
longation due to methadone there are 26 case re-
ports or series documenting QTc prolongation [30–
–56]. In addition, a number of cohort studies suggest
important effects of methadone on the QTc interval.
For example, Maremmani et al. [42] showed 83%
of methadone-treated patients had a more prolon-
ged QTc interval than the reference values for per-
sons of the same sex and age. No correlation emer-
ged between QTc values and methadone dosages.
In a Swiss cohort, 16% demonstrated a QTc > 500 ms,
and six of their patients (3.6%) developed TdP.
In that study, the QTc correlated with methadone
dose [31]. In a study from Copenhagen among
393 methadone treated patients (dose > 100 mg),
32% had a QTc > 440 ms, and 8 patients exhibited
a QTc > 500. They found the QTc increased by
~0.140 ms for each 1 mg increase in daily metha-
done dose. Additionally, odds for reporting any syn-
cope were 1.2 (95% CI 1.1–1.4) times higher when
the methadone dose was increased by 50 mg. This
study included 43 buprenorphine-treated patients,
and 0% of these had QTc > 440 ms [33].
A prospective randomized controlled trial has
only reinforced these data [53]. Levomethadyl ace-
tate, methadone (high and low dose) and buprenor-
phine were compared in a cohort of 220 opioid-ad-
dicted individuals with a normal pre-drug QTc
during a 17-week study. Levomethadyl acetate
(LAAM) is a opioid derived from methadone that
was recently removed from the market [57]. Due
to ethical concerns of using a placebo in a popula-
tion who were judged to need medical therapy, the
‘control’ arm was randomized to 20 mg of metha-
done; however this group was not included in the
QT analysis due to an 80% attrition rate. Using
stringent QTc criteria defining a prolonged QTc
as > 470 ms for men and > 490 ms for women, the
odds ratio (OR) for QTc prolongation on methado-
ne was 14.4 compared to buprenorphine (CI 1.9–
–109.5, p = 0.01). Overall, 12% of the methadone
group and only 2% of the buprenorphine group exhi-
bited an increase from baseline QTc exceeding
60 ms or more, resulting in an OR 8.4 (95% CI 1.9–
–36.4, p < 0.004). On average they had a 34 ms in-
crease in the QTc, three times the amount of the
buprenorphine group (11.3 ms, p = NS, Fig. 3A).
An unexpected finding was progressive QTc
prolongation in the subgroup who were maintained
on a fixed dose of methadone (Fig. 3B). Importan-
tly, six of 52 (11.5%) in the methadone group and
0% in buprenorphine group had a QTc > 500 ms
[53, 58].
Methadone’s association
with torsade de pointes
There are 15 case reports or case series repor-
ting TdP with methadone [31, 32, 34, 35, 37, 39–41,
45, 46, 48–50, 55, 56]. Krantz et al. [39] first repor-
ted 17 episodes of TdP associated with very high
dose methadone, mean 397 ± 283 mg. The Food
and Drug Administration MedWatch system docu-
ments 43 cases of TdP associated with methadone;
8% were fatal and most involved doses of metha-
done exceeding 100 mg/day [46]. One recent series
from the Massachusetts General Hospital conduc-
ted between 1999 and 2007 followed eight patients
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with a history of TdP while enrolled in a methado-
ne maintenance program after re-challenge with
methadone following implantation of a defibrillator.
All but one had preserved left ventricular function
on transthoracic echo (ejection fraction mean 61 ±
± 1.1%), and none had evidence of coronary artery
disease by myocardial perfusion scintigraphy or left
heart catheterization. All of the patients had pro-
longed QTc intervals (mean 613 ± 71 ms) while
taking methadone. One subject died due to undeter-
mined causes, and three of the remaining seven had
multiple recurrent defibrillations for TdP during
a mean follow-up period of 27 months [45]. Of the
six subjects who had ECGs prior to methadone, three
had QTc ≥ 450 ms, which further supports the utili-
ty of baseline ECG screening to measure the QTc
interval prior to initiating therapy with this agent.
Additional risk factors for mortality
in methadone treatment
Several studies have found an increased inci-
dence of mortality during first 14 days of therapy
[59]. Additionally, subjects found at autopsy to have
methadone in their blood frequently did not have
prescriptions for that compound, suggesting it had
been ‘diverted’ from someone else and may repre-
sent a first exposure to the drug [10]. This appa-
rent early increase in mortality may represent re-
spiratory suppression in a naïve individual, but
experience with QTc prolonging drugs (such as
quinidine) also identifies the early treatment period
as a time of high risk for TdP [60]. Data from cani-
ne myocytes exposed to dofetilide suggest that
exposure to IKr blockers induces a compensatory
increase in IKs within 24 hours; early tolerance to
QTc prolongation may develop relatively rapidly
[61]. Benzodiazepines are frequently found in the
blood of someone who suffers a methadone-related
death. While combining benzodiazepines with me-
thadone may simply increase respiratory depres-
sion, an alternative explanation may be that some
benzodiazepines block IKs [62], and may further
reduce repolarization reserve and trigger a greater
QTc prolongation [63].
Other contributory toxic effects of methadone
include its association with sleep apnea. Sleep
apnea itself is associated with bradycardia [64] and
significant QTc prolongation [65], both independen-
tly associated with TdP [28, 29]. Wang found that
30% of those on methadone had central sleep
apnea vs. 0% in body mass index matched controls.
The methadone group also had significantly higher
waking PaCO2, consistent with depressed ventila-
tory drive [66]. How methadone compares to other
opioids with respect to sleep apnea is not described
in the literature and further studies are needed.
Nonetheless, sleep apnea has been shown to cause
QTc prolongation in subjects in the absence of QTc-
-prolonging drugs [65], and so these two mechanisms
may be synergistic in their tendency to promote
sudden death during methadone therapy.
Figure 2. Comparison of the mean rate of Bazett’s corrected QT interval (error bars indicate confidence intervals).
A. Comparison in the three study groups during the trial. Filled symbols indicate significant Tukey post hoc compari-
sons between treatment weeks and week 0 (p < 0.05). Asterisks indicate significant Tukey post hoc comparisons to
buprenorphine hydrochloride group at that treatment week (p < 0.05); B. Comparison in the levomethadyl acetate
and methadone hydrochloride groups receiving a fixed dose of the study drug for at least two 4-week intervals. Filled
symbol indicates a statistically significant difference compared with the first steady state period (p < 0.05).
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Recommendations to clinicians
A committee consisting of cardiologists, pain
specialists, and opioid addiction specialists recently
published a scientific consensus statement with
recommendations for managing patients initiating
or continuing methadone therapy (see Table 2) [67].
In brief, the recommendations are similar to those
in place for dofetilide or other potent QTc-prolon-
ging drugs [68], and include counseling patients
about the risks of TdP, examination of a pre-drug
ECG to identify those with QTc of 450 or greater,
a repeat ECG at one month, and yearly ECGs or
whenever the dose exceeds 100 mg. Patients with
QTc > 500 ms should be evaluated for dose reduc-
tion or alternative therapy. Based on the evolving
literature in this area, it is reasonable to limit the
use of benzodiazepines or drugs (such as fluoxetine)
which inhibit the CYP3A4 hepatic enzyme. In
one prospective cohort study, methadone was
associated with increased QTc interval dispersion,
a marker of arrhythmia risk [67]. In this study, the
presence of anti-depressant therapy was an inde-
pendent predictor of QTc prolongation among
methadone-maintained patients after multivariate
adjustment.
Future directions
Methadone is an important cause of sudden
death in the US. QTc prolongation associated with
methadone has been clearly established, but TdP
remains difficult to predict. A potential future alter-
native therapy, not yet available in the US, is the
non-racemic (R) methadone formulation. It appears
to exhibit less hERG channel blockade than stan-
dard (R,S) methadone and could prove a safe thera-
peutic alternative [30, 69].
Methadone (R,S) may also be a good candidate
drug for evaluating new modalities for risk stratifi-
cation because it is typically given to patients
without structural heart disease or other conditions
that can delay or de-stabilize cardiac repolarization
independently. Measuring QTc variability on
24 hour digital Holter has recently become feasible
and may be a useful modality to examine the con-
tribution of inadequate repolarization reserve in pre-
-drug subjects. Hinterseer et al. [70] recently found
that subjects who experienced drug induced TdP
have increased beat-to-beat QTc variability even in
the off-drug state. Other novel approaches to repola-
rization instability, such as T wave alternans by the
modified moving average method and T wave varia-
bility can be assessed using high frequency digital
Holters, and future studies of QTc-prolonging agents
are likely to benefit from these techniques [71].
Conclusions
Methadone and other opioids are being widely
prescribed for chronic pain, yet methadone-associa-
ted mortality is rising out of proportion to its pre-
scriptions. This increase in deaths likely in part
reflects unrecognized arrhythmia, though acciden-
tal overdose given methadone’s potency and com-
plex pharmacokinetics are also important alterna-
tive or synergistic mechanisms. Unlike other opio-
ids, methadone is a potent hERG blocker carrying
an undeniable proarrhythmic effect. Buprenorphine
and extended release morphine have significantly
fewer QTc-prolonging consequences and appear
to have less morbidity in terms of TdP and
Table 2. 2009 Consensus Recommendations for Physicians Prescribing Methadone [67].
Recommendations
1 (Disclosure) Clinicians should inform patients of arrhythmia risk when they prescribe methadone.
2 (Clinical history) Clinicians should ask patients about any history of structural heart
disease, arrhythmia, and syncope.
3 (Screening) Obtain a pretreatment electrocardiogram for all patients to measure the QTc interval
and then a follow-up electrocardiogram within 30 days and annually. Additional
electrocardiography is recommended if the methadone dosage exceeds 100 mg/d.
or if patients have unexplained syncope or seizures.
4 (Risk stratification) If the QTc interval is greater than 450 ms but less than 500 ms, discuss potential risks
and benefits with patients and monitor them more frequently. If the QTc interval
exceeds 500 ms, consider discontinuing or reducing the methadone dose;
eliminating contributing factors, such as drugs that promote hypokalemia;
or using an alternative therapy.
5 (Drug interactions) Clinicians should be aware of interactions between methadone and other drugs that
possess QT interval–prolonging properties or slow the elimination of methadone.
216
Cardiology Journal 2009, Vol. 16, No. 3
www.cardiologyjournal.org
sudden cardiac death. Oxycodone has recently been
shown to be a weak hERG channel blocker (IC50
171 µM compared to 10 µM for methadone), but no
significant QTc prolongation was noted in the co-
hort study. Nevertheless, further study is needed
before oxycodone can be recommended as an ap-
propriate alternative to methadone in subjects with
QTc prolongation or TdP [72]. Further research
must identify the critical co-variants and risk
factors contributing to methadone-associated mor-
tality, such as the prevalence of susceptible hERG
mutations, variability in opioid respiratory depression,
interaction with pre-existing sleep apnea and poten-
tial for effective treatment of obstructive sleep ap-
nea, and the role of other compounds with synergi-
stic effects. Until newer and better risk-stratifying
strategies are developed, we recommend the use
of screening 12-lead ECGs among patients treated
with methadone to improve the safety of this impor-
tant agent [67]. Clinicians need to be aware that an
increasing number of their patients will be exposed
to methadone, and exercise significant caution when
adding additional drugs to their regimens that may
interfere with its metabolism or provoke additional
QTc prolongation. Finally, the evaluation of une-
xplained syncope or cardiac arrest needs to include
the appropriate toxicologic screening to rule out the
presence of methadone, a compound responsible for
an increasing number of unexplained deaths.
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